Inventiva S.A. American Depositary Receipt
Inventiva S.A. American Depositary Receipt represents Inventiva S.A., a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical need. The company’s current research and development activities center on treatments for metabolic, fibrotic, inflammatory, and rare diseases, with a pipeline that includes programs in liver disease, oncology, fibrosis, and mucopolysaccharidoses. Inventiva S.A. operates as a biotechnology company with international clinical development activity, combining in-house discovery capabilities with late-stage and earlier-stage therapeutic programs. As an American Depositary Receipt, it provides U.S. market access to the company’s ordinary shares and reflects its role as a cross-border biotech issuer with exposure to specialty drug development and clinical research.
$2.94
-$0.17 (-5.47%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-2964.15% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 51.3% YoY. Margins deteriorated 1942.3pp alongside, both lines moving the wrong way.
ROIC dropped from -161.74% to -183.87%, capital efficiency is deteriorating. Negative free cash flow of -€105M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€4M
▼ -51.3% YoY
Net Income (TTM)
-€354M
▼ -92.2% YoY
Op. Margin
-2964.15%
▼ -1942.3pp YoY
ROIC
-183.87%
▼ -22.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€105M
▼ -21.9% YoY
Op. Cash Flow (TTM)
-€105M
▼ -22.1% YoY
Net Debt
-€171M
Net Cash Position
Cash & Equiv.
€231M
3Y CAGR: -28.3%
Continue Research
Is Inventiva S.A. American Depositary Receipt (IVA) overvalued?
Inventiva S.A. American Depositary Receipt (IVA)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Inventiva S.A. American Depositary Receipt scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Inventiva S.A. American Depositary Receipt a high-quality business?+
Inventiva S.A. American Depositary Receipt scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -2,964.2% operating margin and a -183.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Inventiva S.A. American Depositary Receipt a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh IVA's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.